Latest news with #Ferring
Yahoo
2 days ago
- Business
- Yahoo
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Wire
24-04-2025
- Business
- Business Wire
U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN ® (nadofaragene firadenovec-vncg)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN ® (nadofaragene firadenovec-vncg). The approval expands Ferring's manufacturing capabilities to three cutting-edge sites dedicated to bringing ADSTILADRIN to patients and secures a final $200 million payment from Royalty Pharma (Nasdaq: RPRX) as part of a royalty-based financing agreement announced in 2023. ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the FDA for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1). Bladder cancer is the sixth most diagnosed cancer in the United States, and the majority of patients are diagnosed with non-muscle invasive disease. 1 'The FDA approval of our new manufacturing facility for ADSTILADRIN represents our unwavering dedication to delivering high-quality, innovative therapies at scale,' said Armin Metzger, Executive Vice President, Chief Technical Operations Officer, Ferring Pharmaceuticals. 'This expansion and diversification of our manufacturing footprint will further ensure stable and sustainable supply of ADSTILADRIN to meet the anticipated growth in global demand.' Located on Ferring's U.S. campus in Parsippany, NJ, the new state-of-the-art manufacturing site features a cutting-edge manufacturing suite, fully integrated with specialized modern technology and equipment to produce another source of supply for ADSTILADRIN. The 12,000 square foot facility features renewable energy solutions such as waste heat recovery with heat pumps and solar energy, complementing Ferring's commitment to protect the environment by reducing its impact on the planet. ' ADSTILADRIN has transformed the treatment landscape for BCG-unresponsive bladder cancer patients and drives Ferring's continued growth in uro-oncology, ' said Bipin Dalmia, Global Head of Uro-Oncology and Urology Franchise, Ferring Pharmaceuticals. 'The growing body of clinical evidence for ADSTILADRIN — including the recently announced independent real-world data 2 and data from our Japan Phase 3 trial 3 — underscores the impact of this therapy. The FDA's approval of this additional manufacturing site is a testament to our commitment to make ADSTILADRIN globally available to every bladder cancer patient who needs it.' About ADSTILADRIN ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter directly into the bladder once every three months. The vector enters the cells of the bladder wall, releasing the active gene and causing the bladder's cell walls to secrete high and transient local expression of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This approach essentially turns the bladder wall cells into interferon microfactories, enhancing the body's own natural defenses against the cancer. ADSTILADRIN has been studied in a clinical trial program that includes 157 patients with high-risk, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit from additional BCG treatment. 4 The pivotal Phase 3 study met its primary endpoint, with more than half (51%) of the 98 patients (95% CI [41%, 61%]) with CIS with or without papillary tumors (±Ta/T1) achieving a complete response (CR) by three months (full inclusion criteria published on NCT02773849). 4 Earlier this month, Ferring announced results from an ongoing Phase 3 trial of ADSTILADRIN in BCG-unresponsive CIS ± high-grade Ta/T1 patients (n=20) in Japan. At 3 months, 75% (15/20) of patients achieved a complete response. 2 Overall, 80% of participants experienced a drug–related AE, all of which were either Grade 1 (84.2%) or Grade 2 (15.8%). The data from Japan add to the growing body of evidence, including recent real-world data presented by the Mayo Clinic that showed a 79% CR rate, demonstrating consistent effectiveness and safety when patients are treated with ADSTILADRIN at three months (19/24 patients with CIS +/- Ta/T1). 3 Ferring is leading the future in uro-oncology treatment with ADSTILADRIN at the center, while expanding access with the support of new, state-of-the-art manufacturing facilities. As announced in January 2024, ADSTILADRIN is fully available and accessible in the U.S. ADSTILADRIN has confirmed 99 percent coverage for commercial and government-insured patients. As of April 1, 2024, in accordance with the Centers for Medicare and Medicaid Services (CMS), ADSTILADRIN established an Average Sales Price (ASP). Since the establishment of ASP, all covered claims submitted for reimbursement have received payment within an average of 25 days. 5 About Ferring Uro-Oncology Ferring is committed to investing in novel therapies, developing life-changing solutions that address unmet medical needs, and aiding the uro-oncology community in helping patients live better lives. More information is available in the U.S. at and on the dedicated Ferring Uro-Oncology channels on LinkedIn and X. About Non-Muscle Invasive Bladder Cancer (NMIBC) NMIBC is a form of bladder cancer that is found in the inner layer cells of the bladder and does not invade into or beyond the muscle wall. 6 In the United States, bladder cancer is the sixth most common cancer, 1 fourth among men, 7 and it is estimated that there will be approximately 84,870 new cases of bladder cancer in the U.S. in 2025. 1 Historically, 75% of bladder cancer presents as NMIBC. 8 In patients with high-risk NMIBC, intravesical BCG remains the first-line standard-of-care. However, approximately one third of patients with NMIBC will not respond to BCG therapy and 50% of those with an initial response will experience recurrence or progression of their disease. 9 Current treatment options for BCG-unresponsive patients are very limited, and National Comprehensive Cancer Network (NCCN) guidelines recommend cystectomy (partial or complete removal of the bladder). 10 INDICATION ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product. WARNINGS AND PRECAUTIONS: Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy. Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals. DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration. USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose. ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination). You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING. Please click to see the full Prescribing Information. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees. For more information, please visit call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn, and X. References: American Cancer Society. Cancer Facts & Figures 2025. Available at: Accessed April 22, 2025. Moyer J, Durant A, Nguyen M. Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer. Presented at the Annual Meeting of the American Society of Clinical Oncology GU, February 2025. Inoue K, Kikuchi E, Nishiyama H, Nasu Y, et al. Efficacy and Safety of Nadofaragene Firadenovec for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Initial Results From an Ongoing Japanese Phase 3 Trial. Presented at the 112 th Annual Meeting of the Japanese Urological Association, April 22, 2025. Available at: ADSTILADRIN in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). Gov Identifier: NCT02773849. Available at: Accessed April 22, 2025. Ferring Access Support benefits investigations for commercial and government-insured patients through March 15, 2024. Urology Care Foundation. Non-muscle Invasive Bladder Cancer. Available at: Accessed April 22, 2025. National Cancer Institute. Cancer Statistics. Available at: Accessed April 22, 2025. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 Jan;81(1):75-94. Lidagoster S, et al. BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer. Curr Oncol. 2024 Feb 16;31(2):1063-1078. doi: 10.3390/curroncol31020079. National Comprehensive Cancer Network. Bladder Cancer (Version 1.2025). Available at: Accessed April 22, 2025. More information is available at the following:
Yahoo
21-04-2025
- Business
- Yahoo
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1
First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological Association, highlighting Ferring's ongoing commitment to establish the new standard of care in BCG-unresponsive NMIBC1 Results showed 75% complete response rate at three months in high-risk BCG-unresponsive NMIBC patients (n=20) receiving nadofaragene firadenovec (marketed as ADSTILADRIN® in the US) and is in addition to the independent real-world data presented earlier this year that showed a 79% complete response rate2 Safety profile shows all treatment-related adverse events were Grade 1 (84.2%) or Grade 2 (15.8%), with no Grade 3, 4, or 5 adverse events reported1 SAINT PREX, Switzerland, April 21, 2025--(BUSINESS WIRE)--Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).1 Nadofaragene firadenovec is the first and only intravesical non-replicating gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.2 The product is given once every three months. The data – presented at the 112th Annual Meeting of the Japanese Urological Association (JUA 2025) held April 17-19 in Fukuoka, Japan – showed a complete response (CR) rate at three months of 75% (15/20) among Japanese patients with CIS ± high-grade Ta/T1.1 Importantly, these results were achieved following a single quarterly administration, representing a significant clinical advantage. The efficacy appears higher than previously reported in the US Phase 3 trial3,4 and adds to a growing body of evidence. Recent real-world data was presented by the Mayo Clinic and showed 79% CR rate,2 demonstrating consistent efficacy and safety when patients are treated with nadofaragene firadenovec. Patients who responded at the three-month assessment received continued every three months doses until disease recurrence. These data will be presented at a future congress. Within this conservatively designed protocol, a replication of CS-003 US Phase 3 trial, patients who did not respond at three months were not offered a re-induction dose. This contrasts with a growing trend in other NMIBC trials, where re-induction is included in the study protocols for patients who do not achieve a response at initial assessment. Re-induction is now being explored with nadofaragene firadenovec in other trials. "When BCG therapy is ineffective, patients are forced to choose invasive surgery, i.e., total bladder removal, but nadofaragene firadenovec may provide a new treatment option," noted Professor Keiji Inoue, M.D., Ph.D., Department of Urology, Kochi Medical School. "These findings are particularly significant for Japanese patients, as our treatment options have been more limited compared to other regions. The ability to achieve such promising results represents an important advancement for our clinical practice." Overall, 80% of participants (16 patients) experienced drug-related adverse events (AEs), with 76 total AEs recorded. All reported AEs were either Grade 1 (64 AEs in 15 participants, 84.2%) or Grade 2 (12 AEs in 5 participants, 15.8%). No Grade 3, 4, or 5 AEs were reported, demonstrating a clinically manageable and tolerable safety profile. The data from Japan add to the growing body of evidence, including recent real-world data presented by the Mayo Clinic,2 demonstrating favorable efficacy and safety when patients are treated with nadofaragene firadenovec. "At Ferring, we are committed to meeting the unmet needs in bladder cancer care and equipping uro-oncologists with critical evidence they need to deliver effective, and life-changing treatment," said Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals. "These new Phase 3 findings affirm the safety profile of nadofaragene firadenovec, demonstrating a three-month efficacy that is higher than previously reported in our Phase 3 clinical trial, and complements results from an ongoing independent real-world study presented earlier this year. Collectively, the data are broadening our understanding of the value that nadofaragene firadenovec offers, furthering our journey to establish nadofaragene firadenovec as the new standard of care and backbone therapy across the urothelial cancer disease spectrum." Bladder cancer is the 9th most common cancer worldwide by incidence, with approximately 614,000 new cases diagnosed each year.5 Non-muscle invasive bladder cancer (NMIBC) accounts for about 75% of all newly diagnosed bladder cancers.6 For patients who do not respond to BCG treatment, current options are limited, often leading to invasive surgery involving complete bladder removal. The strong efficacy demonstrated in this Japanese patient population suggests nadofaragene firadenovec could address a critical unmet need in the bladder cancer treatment landscape, delaying radical cystectomy and preserving quality of life for thousands of patients annually. The ongoing Phase 3 Japanese trial is evaluating the efficacy and safety of nadofaragene firadenovec in two cohorts of high-risk BCG-unresponsive NMIBC patients: those with CIS ± HG Ta/T1, and patients with papillary tumors (Ta/T1) only. Results from the cohort with CIS ± HG Ta/T1 were presented on April 19 at JUA 2025.1 About nadofaragene firadenovec Nadofaragene firadenovec (marketed as ADSTILADRIN® in the US) is the first and only FDA-approved intravesical non-replicating gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter directly into the bladder once every three months. The vector enters the cells of the bladder wall, releasing the active gene and causing the bladder's cell walls to secrete high and transient local expression of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This approach essentially turns the bladder wall cells into interferon microfactories, enhancing the body's own natural defenses against cancer. Nadofaragene firadenovec has been studied in a clinical trial programme that includes 157 patients with high-risk, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit from additional BCG treatment (full inclusion criteria published on NCT02773849).3 Final 60-month follow-up data demonstrated an 80% overall survival rate and 49% cystectomy-free survival rate in adult patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors (±Ta/T1), and in patients with high-grade Ta/T1 without CIS5. Most treatment emergent AEs (AEs) at five years were transient Grade 1 or 2 (66% of all patients studied), and <4% of patients experienced Grade 3 AEs with the most common being discharge around the catheter during instillation, fatigue, bladder spasm, urgency to urinate, chills, dysuria, pyrexia, and urinary incontinence. There were no Grade 4 or 5 AEs, no treatment-related deaths, and no new safety signals reported with long-term follow-up. Ferring is leading the future in uro-oncology treatment with nadofaragene firadenovec at the centre, while expanding access with the support of new, state-of-the-art manufacturing facilities. About Non-Muscle Invasive Bladder Cancer (NMIBC) NMIBC is a form of bladder cancer which is present in the superficial layer of the bladder and has not invaded deeper into the bladder or spread to other parts of the body. Bladder cancer is the ninth most commonly diagnosed cancer globally. 75% of bladder cancers present as NMIBC.7 In patients with high-risk NMIBC, intravesical BCG remains the first-line standard of care. However, more than 50% of patients who receive initial treatment with BCG will experience disease recurrence and progression within one year, with many developing BCG-unresponsive disease.7 Current treatment options for BCG-unresponsive patients are very limited, and National Comprehensive Cancer Network (NCCN) guidelines recommend cystectomy (partial or complete removal of the bladder). About Ferring Pharmaceuticals Ferring Pharmaceuticals a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries. Learn more at or connect with us on LinkedIn, Instagram, YouTube, Facebook and X. 1 Inoue K, Kikuchi E, Nishiyama H, Nasu Y, et al. Efficacy and Safety of nadofaragene firadenovec for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Initial Results From an Ongoing Japanese Phase 3 Trial. Presented at the 112th Annual Meeting of the Japanese Urological Association, April 19, 2025. Available at: 2 Moyer J, Durant A, Nguyen M. Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer. Presented at the Annual Meeting of the American Society of Clinical Oncology GU, February 2025.3 ADSTILADRIN | FDA 4 Boorjian SA, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1): 107-117.5 Narayan VM, at al. Efficacy of Intravesical nadofaragene firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial. J Urol. 2024 May 5. doi: 10.1097/JU.00000000000040206 World Cancer Research Fund International. Bladder cancer statistics. Available at: Last accessed: March 2025.7 Deng S, et al. Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis. Front Oncol. 2022; 12:1044830.8 Babjuk M, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94. View source version on Contacts For more information, please contact Tara Breen Director, Corporate Communications +44 Sign in to access your portfolio
Yahoo
03-03-2025
- Science
- Yahoo
American Spacecraft Touches Down on Moon, Sends Back Photos
Texas-based space company Firefly Aerospace's Blue Ghost lander has become the second private spacecraft in history to softly touch down on the Moon's surface. In fact, the company claimed in an announcement that it was the first to "successfully" do so, effectively arguing that Intuitive Machines' Odysseus lander failed when it toppled over during its attempt last year (Odysseus failed to reestablish connection with the Earth a month after landing on the Moon). Firefly's car-sized lander touched down within its target landing zone in the Mare Crisium, a massive basin on the Moon's near side. It's since sent back several photographs, showing it settled on the rocky surface with the Earth glinting in the distance. One image even shows its own shadow as the Sun slowly rises. It's yet another sign that the Moon's surface is back within reach over half a century after NASA's Apollo program launched its final mission — and building buzz around the space agency's first crewed lunar mission since then, which is still tentatively scheduled for mid-2027. Blue Ghost will spend the next lunar day — the equivalent of 14 Earth days — studying the lunar environment on behalf of NASA's Commercial Lunar Payload Services program. On March 14, it'll take high-definition images of the Earth eclipsing the Sun from its perspective. On Earth, onlookers will be able to observe a total lunar eclipse, which will turn the Moon a deep red. "With the hardest part behind us, Firefly looks forward to completing more than 14 days of surface operations, again raising the bar for commercial cislunar capabilities," said Firefly CTO Shea Ferring in a statement. Blue Ghost carries ten different scientific instruments on behalf of NASA. Its "surface operations include lunar subsurface drilling, sample collection, X-ray imaging, and dust mitigation experiments," according to the company. "We want to thank NASA for entrusting in the Firefly team, and we look forward to delivering even more science data that supports future human missions to the Moon and Mars," Ferring said. Blue Ghost is the first of three landers to attempt to land on the Moon within the next few months. Houston-based company Intuitive Machines' Athena lander — the followup to the one that didn't stick the landing — will attempt to land on the lunar surface as soon as Thursday. And Japanese space company ispace's Hakuto-R Mission 2 will make its attempt later this spring. Firefly's lander has downlinked an astonishing 27 gigabytes of data over the last 45 days. And considering the many photo opportunities coming up soon, we can't wait to check out the next batch of images. More on the landers: Robot With Large Drill Headed for Surface of Moon
